Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2009

Agalliu Ilir, Gern Robert, Leanza Suzanne, Burk Robert D

Abstract excerpt

PURPOSE: Protein-truncating mutations in BRCA1 and in particular BRCA2 genes have been associated with prostate cancer. However, there is still uncertainty about the magnitude of association particularly with Gleason score, and family history of prostate, breast, and ovary cancers. EXPERIMENTAL DESIGN: To further examine associations between three founder mutations located in BRCA1 (185delAG, 5382insC) or BRCA2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Family Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Founder Effect

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Testing

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 19188187
DOI: 10.1158/1078-0432.CCR-08-1822
PMCID: PMC3722558

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.PMID 19188187Read ↗

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.Semantic proximity Read ↗

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancerSemantic proximity Read ↗

BRCA mutations and risk of prostate cancer in Ashkenazi Jews.Semantic proximity Read ↗

Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.Semantic proximity Read ↗

Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.Semantic proximity Read ↗

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.Semantic proximity Read ↗

A twofold increase in <i>BRCA</i> mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathologySemantic proximity Read ↗

Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.Semantic proximity Read ↗

The role of the BRCA2 gene in susceptibility to prostate cancer revisited.Semantic proximity Read ↗

The role of BRCA1 and BRCA2 in prostate cancer.Semantic proximity Read ↗

Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease.Semantic proximity Read ↗

Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.